APA (7th ed.) Citation

MA, S., M, L., R, F., UJ, M., D, S., B, P., . . . P, L. (2021). Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors. Nature communications, 12(1), 3807. https://doi.org/10.1038/s41467-021-24069-w

Chicago Style (17th ed.) Citation

MA, Schneider, et al. "Phase Ib Dose-escalation Study of the Hypoxia-modifier Myo-inositol Trispyrophosphate in Patients with Hepatopancreatobiliary Tumors." Nature Communications 12, no. 1 (2021): 3807. https://doi.org/10.1038/s41467-021-24069-w.

MLA (9th ed.) Citation

MA, Schneider, et al. "Phase Ib Dose-escalation Study of the Hypoxia-modifier Myo-inositol Trispyrophosphate in Patients with Hepatopancreatobiliary Tumors." Nature Communications, vol. 12, no. 1, 2021, p. 3807, https://doi.org/10.1038/s41467-021-24069-w.